



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office. T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax 0091-11-26498341, 26494708, Phone: 0091-11-46181100, 46109900
Email: nandita.singh@jagsonpal.com
CIN No.: L74899DL1978PLC009181

Date: November 24th, 2022

To, The Department of Corporate Services- Listing Bombay Stock Exchange Ltd, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400 001	To, National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051
Scrip Code: 507789	Symbol: JAGSNPHARM

**SUB: Disclosure of Related Party Transaction under Regulation 23(9) of the SEBI
(Listing Obligations and Disclosure Requirements Regulations, (Amendments)
2018.**

Dear Sir,

Pursuant to Regulation 23(9) of the SEBI Listing Regulations, please find enclosed herewith disclosures of related party transactions on consolidated basis in the revised format, as prescribed under SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated 22nd November 2021, for the half year ended commencing from 01 April, 2022 to 30 September, 2022.

This is for your information and records.

Thanking You,

For JAGSONPAL PHARMACEUTICALS LIMITED

NANDITA SINGH Digitally signed by
NANDITA SINGH
Date: 2022.11.24
A SINGH 12:04:30 +05'30'

Nandita Singh
Company Secretary and Compliance Officer

Encl. as above

General information about company

Name of The Company	JAGSONPAL PHARMACEUTICALS LIMITED
BSE Scrip Code	507789
NSE Symbol	JAGSNPHARM
MSE Symbol	NOTLISTED
Date of Start of Financial Year	01-04-2022
Date of End of Financial Year	31-3-2023
Reporting Period	First half yearly
Date of Start of Reporting Period	01-04-2022
Date of End of Reporting Period	30-09-2022
Level of rounding to be used in disclosing related party transactions	Lakhs
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes

(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (g), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	

Related party transactions

											Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments					Notes			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)		Interest Rate (%)	Tenure	Secured/ unsecured
1	JAGSONPAL PHARMACEUTICALS LIMITED	AAACJ1408L	Naari Pharma Pvt Ltd	AAACI2995R	Associate Company	Purchase of goods or services		89.54	Approved	89.54	0	0									Textual Information(1)
2	JAGSONPAL PHARMACEUTICALS LIMITED	AAACJ1408L	Rajpal Singh Kochhar	AALPK5264B	Managing Director till 16.07.2022	Remuneration		30.24	Approved	30.24	0	0									Textual Information(2)
3	JAGSONPAL PHARMACEUTICALS LIMITED	AAACJ1408L	Ashok Kumar Pati	AARPP3739Q	Independent Director till 29.06.2022	Any other transaction	Sitting Fees	0.035	Approved	0.035	0	0									Textual Information(3)
4	JAGSONPAL PHARMACEUTICALS LIMITED	AAACJ1408L	Bharat Sinh	AMCPS1407M	Independent Director till 29.06.2022	Any other transaction	Sitting Fees	0.505	Approved	0.505	0	0									Textual Information(4)
5	JAGSONPAL PHARMACEUTICALS LIMITED	AAACJ1408L	Ishpal Singh Ghai	ARBPG4228Q	Independent Director till 29.06.2022	Any other transaction	Sitting Fees	0.415	Approved	0.415	0	0									Textual Information(5)
6	JAGSONPAL PHARMACEUTICALS LIMITED	AAACJ1408L	Mammen Mathew	AVQPM2234D	Independent Director till 29.06.2022	Any other transaction	Sitting Fees	0.282	Approved	0.282	0	0									Textual Information(6)
7	JAGSONPAL PHARMACEUTICALS LIMITED	AAACJ1408L	SV Subha Rao	AAHPR8501L	CFO	Any other transaction	Short-term employee benefits	23.83	Approved	23.83	0	0									Textual Information(7)
8	JAGSONPAL PHARMACEUTICALS LIMITED	AAACJ1408L	Nandita Singh	GECPS8677K	CS	Any other transaction	Short-term employee benefits	4.09	Approved	4.09	0	0									Textual Information(8)
9	JAGSONPAL PHARMACEUTICALS	AAACJ1408L	Manish Gupta	AABPG1518N	Managing Director	Remuneration		55.9	Approved	55.9	0	0									Textual Information(9)

